Phase II Randomized, Double-blind, Placebo-controlled, Two-arm Study to Evaluate the Safety and Efficacy of Erlotinib in the Treatment of Moderate to Severe Psoriasis

Trial Profile

Phase II Randomized, Double-blind, Placebo-controlled, Two-arm Study to Evaluate the Safety and Efficacy of Erlotinib in the Treatment of Moderate to Severe Psoriasis

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2014

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Psoriasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 May 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 13 Apr 2011 Planned End Date changed to 1 Jun 2013, according to ClinicalTrials.gov record..
    • 13 Apr 2011 Planned initiation date changed to 1 Jun 2011, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top